Core Viewpoint - The company, CanSino, has successfully positioned its product, Manhaixin®, as the only approved quadrivalent meningococcal conjugate vaccine in China, targeting the mid-to-high-end infant vaccine market, with increasing market acceptance and sales growth indicating strong demand for high-quality vaccines in the domestic market [1] Group 1: Product Development and Market Expansion - Manhaixin® has seen steady sales growth, confirming the demand for premium infant vaccines in China [1] - The company has submitted a supplementary application to expand the age indication for Manhaixin® to children aged 3 months to 6 years and plans to pursue further age expansion for adolescents and adults (ages 7 to 59) [1] - The product has been launched in Indonesia as of September 2025, marking the start of its sales in the local market [1] - The company is actively working to expand the product's market access in other target countries and regions to enhance its influence and benefit a broader population [1] Group 2: Financial Performance - For the third quarter of 2025, the company reported revenue of approximately 693 million yuan, representing a year-on-year increase of 22% [1] - The sales revenue from the meningococcal product reached approximately 662 million yuan in the first three quarters, reflecting a 28% increase compared to the same period last year [1] - The company has announced a new equity incentive plan with revenue growth targets set for 2025, indicating a commitment to achieving these objectives [1]

Core Viewpoint - The company, CanSino, has been deeply engaged in key areas such as meningitis vaccines, pneumonia vaccines, infant vaccines, innovative vaccination schemes, and adult vaccines for many years, and plans to continue enriching its pipeline through advanced technology platforms [1] Group 1: Current Focus Areas - The company is exploring innovative fields and expanding into areas such as tumor vaccines and therapeutic vaccines, aiming to develop differentiated competitive products [1] - mRNA technology is one of the company's leading platforms, recognized for its high platform value and broad development prospects [1] Group 2: Research and Development - The company has accumulated years of experience in the development and production of mRNA vaccines, including in-depth knowledge of infectious diseases and antigen screening [1] - In the therapeutic area, the company is advancing the development of mRNA vaccines for glioblastoma and rhabdomyosarcoma, aiming to expand the application range of its leading technology platform [1] Group 3: Technology and Licensing - The company has achieved external technology licensing for its proprietary new three-component lipid nanoparticle delivery system (ISL-3C-LNP) [1]

Core Viewpoint - The company, CanSino, is focusing on its core business while exploring additional indications in the treatment field using its mRNA technology platform, with updates to be provided upon significant progress [1]. Group 1 - CanSino is committed to enhancing its main business operations [1]. - The company is leveraging its mRNA technology platform for further exploration in treatment indications [1]. - CanSino will announce any significant advancements in its research and development efforts in a timely manner [1].

Group 1 - The core point of the article is that CanSino Biologics has stated that since mid-April 2021, the China National Medical Products Administration (NMPA) no longer publishes the batch release numbers for vaccine products, and the company will follow the information disclosure practices of its peers [1] Group 2 - CanSino Biologics is adapting its information disclosure strategy in response to regulatory changes regarding vaccine batch release data [1]

康希诺生物(6185.HK)今日盘中一度涨3.74%至37.74港元，股价创2025年12月16日以来新高；该股2026年实现开门红，迄今已连续三个交易日上涨，累涨超 8%，跑赢大盘表现(同期恒指累涨超4%)。 康希诺生物昨日晚间公告，公司研发的24价肺炎球菌多糖结合疫苗(CRM197╱破伤风类毒素)("PCV24")已获得中国国家药品监督管理局批准，可以开展相关 临床试验。公司PCV24覆盖当前肺炎球菌主要流行血清型，采用多糖抗原与蛋白载体共价结合的方式，以及双载体技术，拟适用于2月龄(最小6周)及以上人 群接种，以预防由24种肺炎球菌血清型引起的感染性疾病。该产品完成了24种血清型纯化多糖、多糖蛋白结合物原液生产工艺、成品处方的开发与确认。于 本公告日期，24价肺炎球菌多糖结合疫苗在国内外均无上市产品。(格隆汇) ...

每经AI快讯，康希诺生物(06185.HK)一度涨超3%，截至发稿涨2.8%，报37.4港元，成交额3299.01万港 元。 （文章来源：每日经济新闻） ...

消息面上，1月5日，康希诺生物发布公告，公司研发的24价肺炎球菌多糖结合疫苗(CRM197╱破伤风 类毒素)(PCV24)已获得中国国家药品监督管理局批准，可以开展相关临床试验。 康希诺生物(06185)涨超3%，截至发稿，涨2.8%，报37.4港元，成交额3299.01万港元。 公司PCV24覆盖当前肺炎球菌主要流行血清型，採用多糖抗原与蛋白载体共价结合的方式，以及双载体 技术，拟适用于2月龄(最小6周)及以上人群接种，以预防由24种肺炎球菌血清型引起的感染性疾病。该 产品完成了24种血清型纯化多糖、多糖蛋白结合物原液生产工艺、成品处方的开发与确认。于本公告日 期，24价肺炎球菌多糖结合疫苗在国内外均无上市产品。 ...

智通财经APP获悉，康希诺生物(06185)涨超3%，截至发稿，涨2.8%，报37.4港元，成交额3299.01万港 元。 消息面上，1月5日，康希诺生物发布公告，公司研发的24价肺炎球菌多糖结合疫苗(CRM197╱破 伤风类毒素)(PCV24)已获得中国国家药品监督管理局批准，可以开展相关临床试验。 公司PCV24覆盖当前肺炎球菌主要流行血清型，採用多糖抗原与蛋白载体共价结合的方式，以及双载体 技术，拟适用于2月龄(最小6周)及以上人群接种，以预防由24种肺炎球菌血清型引起的感染性疾病。该 产品完成了24种血清型纯化多糖、多糖蛋白结合物原液生产工艺、成品处方的开发与确认。于本公告日 期，24价肺炎球菌多糖结合疫苗在国内外均无上市产品。 ...

深耕肺炎疫苗领域多年，康希诺已积累扎实的技术积淀。2025年9月，公司自主研发的13价肺炎球菌多 糖结合疫苗优佩欣®（PCV13i）正式上市供应，该产品是我国首款采用CRM197与破伤风类毒素（TT） 双载体技术的肺炎球菌结合疫苗。通过创新双载体设计，优佩欣®有效规避了单一载体过量引发的不良 反应风险，减少与其他疫苗共注射时的免疫干扰，显著提升免疫原性，尤其对我国儿童疾病负担最重的 19F、19A、7F、3型等血清型实现精准防护。 在优佩欣®成功上市的基础上，康希诺加速推进高价次疫苗研发进程。此次获批的PCV24疫苗实现关键 技术突破，不仅覆盖当前肺炎球菌主要流行血清型，更延续了双载体技术优势，采用多糖抗原与蛋白载 体共价结合工艺，完成了24种血清型纯化多糖、多糖蛋白结合物原液生产工艺及成品处方的开发与确 认。该疫苗拟适用于2月龄（最小6周）及以上全人群接种，可有效预防24种肺炎球菌血清型引发的感染 性疾病，有望进一步填补高价次肺炎疫苗的市场空白。 2026年新年伊始，康希诺生物(688185)传来研发进展：公司自主研发的24价肺炎球菌多糖结合疫苗 （CRM197/破伤风类毒素，简称"PCV24"）正式获得国 ...

Major Events - Yunzhisheng (09678) secured a regional medical cooperation contract worth over 20 million [1] - Kelun-Biotech (06990) received breakthrough therapy designation from NMPA for TROP2 ADC drug in combination with pembrolizumab for treating PD-L1 positive locally advanced or metastatic non-small cell lung cancer [1] - InSilico Medicine (03696) entered into an 8.88 billion USD multi-year collaboration for anti-tumor drug development with Sihuiya [1] - Hutchison China MediTech (00013) is conducting a Phase III study on surufatinib combined with camrelizumab for first-line treatment of pancreatic ductal adenocarcinoma [1] - Ascletis Pharma-B (01672) announced FDA approval for IND of ASC30 in a 13-week Phase II study in diabetic patients [1] - Foryou Medical (01696) received quality standard inspection approval for its reauthorized injectable botulinum toxin from the Chinese National Medical Products Administration [1] - CanSino Biologics (06185) obtained clinical trial approval in China for its 24-valent pneumococcal polysaccharide conjugate vaccine [1] - Stone Group (02005) received drug production registration approval for perindopril and amlodipine tablets [1] - Sunny Optical Technology (02382) proposed to spin off its automotive optical business for independent listing on the Hong Kong Stock Exchange [1] - Dongyang Sunshine Pharmaceutical (06887) completed the first patient enrollment for HECN30227 in China [1] - Haitong International's subsidiary plans to sell 100% equity of Guohua Machinery for 342 million [1] - Yuexiu Property (00123) subsidiary intends to sell 73.74% actual equity in Hangzhou Yueyun [1] - CIMC Group (02039) subsidiary CIMC Shilianda plans to introduce strategic investors through capital increase and transfer of a small number of old shares [1] Operating Performance - Chifeng Jilong Gold Mining (06693) expects annual net profit attributable to shareholders to be approximately 3 billion to 3.2 billion, an increase of about 70% to 81% year-on-year [2] - Corning Hospital (02120) anticipates outpatient visits to reach approximately 720,200 in 2025, a year-on-year increase of 29% [2] - Seres (09927) reported total vehicle sales of 63,700 units in December, a year-on-year increase of 53.54% [2] - Xiehe New Energy (00182) reported an equity power generation of 790.32 GWh in December [2] - Country Garden (02007) reported contract sales amounting to approximately 2.69 billion attributable to shareholders in December [2]